combretastatin has been researched along with B16 Melanoma in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guchhait, SK; Kumari, A; Manne, RK; Panda, D; Santra, MK; Sisodiya, S; Srivastava, S | 1 |
| Basso, G; Bortolozzi, R; Mitola, S; Porcù, E; Primac, I; Ravelli, C; Romagnoli, R; Ronca, R; Salvador, A; Vedaldi, D; Viola, G | 1 |
| Haselwandter, CA; Kardar, M; Kohandel, M; Sengupta, S; Sivaloganathan, S | 1 |
| Babu, B; Brockway, O; Dandavati, A; Lee, M; Mooberry, SL; Satam, V; Sjoholm, R; Tzou, S; Westbrook, C; Zeller, M | 1 |
| Kiani, MF; Moore, BM; Nallamothu, R; Pattillo, CB; Sari-Sarraf, F; Wood, GC | 1 |
| Capila, I; Eavarone, D; Kiziltepe, T; Sasisekharan, R; Sengupta, S; Watson, N; Zhao, G | 1 |
6 other study(ies) available for combretastatin and B16 Melanoma
| Article | Year |
|---|---|
C12, a combretastatin-A4 analog, exerts anticancer activity by targeting microtubules.
Topics: A549 Cells; Animals; Antineoplastic Agents, Phytogenic; Bibenzyls; Cell Proliferation; Drug Delivery Systems; HeLa Cells; Humans; MCF-7 Cells; Melanoma, Experimental; Mice; Mice, Inbred NOD; Mice, SCID; Microtubules | 2019 |
Vascular disrupting activity of combretastatin analogues.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Antigens, CD; Bibenzyls; Cadherins; Capillary Permeability; Cardiac Myosins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Shape; Cells, Cultured; Chick Embryo; Chorioallantoic Membrane; Dose-Response Relationship, Drug; Focal Adhesion Kinase 1; Human Umbilical Vein Endothelial Cells; Humans; Melanoma, Experimental; Mice, Inbred C57BL; Myosin Light Chains; Neovascularization, Pathologic; Neovascularization, Physiologic; Phosphorylation; Signal Transduction; Time Factors | 2016 |
Quantitative model for efficient temporal targeting of tumor cells and neovasculature.
Topics: Algorithms; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bibenzyls; Biological Availability; Carcinoma, Lewis Lung; Computer Simulation; Doxorubicin; Drug Delivery Systems; Drug Synergism; Liposomes; Melanoma, Experimental; Mice; Models, Biological; Nanoparticles; Neoplasms; Neovascularization, Pathologic; Time Factors; Treatment Outcome | 2011 |
A novel class of trans-methylpyrazoline analogs of combretastatins: synthesis and in-vitro biological testing.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bibenzyls; Cell Line, Tumor; Cell Survival; Crystallography, X-Ray; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Leukemia L1210; Melanoma, Experimental; Mice; Microtubules; Molecular Docking Simulation; Pyrazoles; Stilbenes; Structure-Activity Relationship; Tubulin Modulators | 2011 |
Targeting of the antivascular drug combretastatin to irradiated tumors results in tumor growth delay.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Bibenzyls; Combined Modality Therapy; Drug Delivery Systems; Liposomes; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Stilbenes; Tumor Burden | 2005 |
Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bibenzyls; Carcinoma, Lewis Lung; Coculture Techniques; Doxorubicin; Drug Delivery Systems; Drug Therapy, Combination; Endothelial Cells; Humans; Melanoma, Experimental; Mice; Nanotechnology; Neoplasms; Neovascularization, Pathologic; Stilbenes; Time Factors; Tissue Distribution | 2005 |